TABLE 2.
Summary of rescue pharmacology.
| Parameters | Coexpressed with GluN2A | Coexpressed with GluN2B | ||
|
|
|
|||
| WT GluN1 | GluN1-P532H | WT GluN1 | GluN1-P532H | |
| I(24(S)HC)/I(control) % (n) | 122% (110%, 134%) (8) | 125% (114%, 136%) (10) | 162% (154%, 169%) (7) | 159% (142%, 176%) (12) |
| I(PS)/I(control) % (n) | 315% (186%, 445%) (7) | 260% (213%, 307%) (10) | 382% (324%, 441%) (7) | 331% (268%, 393%) (15) |
| I(tobramycin)/I(control) % (n) | NA | NA | 199% (181%, 216%) (7) | 189% (179%, 198%) (10) |
| I(24(S)HC)/I(control),−60 mV (n) | 1.2 (1.1, 1.3) (5) | 1.3 (1.2, 1.4) (9) | NA | NA |
| I(24(S)HC)/I(control), +30 mV (n) | 1.2 (1.1, 1.2) (5) | 1.2 (1.1, 1.4) (9) | NA | NA |
| I(PS)/I(control),−60 mV (n) | 1.6 (1.4, 1.8) (6) | 2.0 (1.8, 2.2) (6) | NA | NA |
| I(PS)/I(control), +30 mV (n) | 2.2 (1.0, 3.3) (6) | 2.2 (1.6, 2.7) (6) | NA | NA |
| D-Serine, EC50 [μM] (n) | 1.1 (0.90, 1.2) (7) | 0.79 (0.70, 0.88) (10)* | 0.42 (0.37, 0.46) (9) | 0.39 (0.33, 0.46) (14) |
| L-Serine, EC50 [μM] (n) | 180 (169, 191) (6) | 79 (68, 90) (9)* | 82 (74, 91) (7) | 18 (17, 19) (12)* |
| D-Cycloserine, EC50 [μM] (n) | 28 (26, 30) (10) | 12 (11, 13) (10)* | 6.4 (5.1, 7.6) (8) | 5.8 (4.7, 6.9) (11) |
The data were generated by TEVC recordings on Xenopus oocytes (VHOLD: −40 mV, unless otherwise stated) and expressed as mean (−95% CI, +95% CI) (n); CI, confidence interval; (n) is the number of oocytes.
*p < 0.05 indicated when the 95% confidence intervals of the datasets for the variant receptors do not overlap with the wild-type receptors.
NA, not available.